Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hu-Yun-Long Zhang
Observed name:
Hu-Yunlong Zhang
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
State Key Laboratory of Medical Neurobiology,
Frontiers Center for Brain Science of the Ministry of Education
ORCID:
0009-0009-5380-3062
Observed ORCID:
0009-0009-5380-3062
OpenAlex ID:
A5042715988
Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer
2023
·
Shen Zhao
, De-Pin Chen
, et al.
·
Nature Communications
·
93
PDF
Roles of Neuropeptides in Sleep–Wake Regulation
2022
·
Yi-Chen Shen
, Xiao Sun
, et al.
·
International Journal of Molecular Sciences
·
62
PDF
Interferon-induced senescent CD8 + T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer
2025
·
Tong Fu
, Xi Jin
, et al.
·
Science Translational Medicine
·
31
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
·
Cancer Research
·
11
Adenosine A2A receptor neurons in the olfactory bulb mediate odor-guided behaviors in mice
2021
·
Xiao Sun
, Lei Li
, et al.
·
Brain Research
·
5
Abstract PO1-15-07: Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial
2024
·
Xiu-Zhi Zhu
, Xi Jin
, et al.
·
Cancer Research
·
2
Decoding neutrophil spatial heterogeneity and clinical implications in breast cancer
2026
·
Yu-Zheng Xu
, Xiang-Rong Wu
, et al.
·
Cancer Cell
·
1
Abstract PO1-15-09: Vitamin A Metabolism Induces Ferroptosis to Enhance Immune Therapy Efficacy in HR+/HER2- Breast Cancer
2024
·
Yi-Fan Zhou
, Hu-Yun-Long Zhang
, et al.
·
Cancer Research
·
1
Table S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Data from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Show more works
View as search
Works count:
25
Citation count:
206
H-index:
5
I10-index:
4
Year
Topic
Type